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AntiviralAbstract In this paper, a variety of 1-aryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing
1,3,4-oxadiazole moiety were designed and synthesized. Preliminary bioassays suggested that these
compounds not only exhibited favorable antibacterial activity toward plant pathogenic bacteria
including Xanthomonas oryzae pv. oryzae (Xoo), Ralstonia solanacearum (R. solanacearum), and
Xanthomonas axonopodis pv. citri. (Xac), but also demonstrated certain curative and protective
activities against Tobacco mosaic virus (TMV). Further studies revealed that compounds 8a and
8l exerted the best inhibition effect against Xoo with the half-maximal effective concentration
(EC50) values of 8.6 and 7.3 lg/mL, respectively, which were better than that of commercial agri-
cultural antibacterial bismerthiazol (EC50 = 92.6 lg/mL). Given the above results, this kind of
compounds can be further studied and explored as alternative antibacterial agents.
 2016 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Natural heterocyclic substructures play a key role in the devel-
opment and creation of pharmaceuticals and agrochemicals
[1–3]. In the past decades, all sorts of bioactive compounds
were constructed based on natural skeletons [4–5]. Tetramic
acid, an attractive scaffold, existing in a 4-hydroxy-1H-
pyrrol-2(5H)-one or pyrrolidine-2,4-dione form, was
discovered in a variety of natural products from marine
organisms, bacteria, and fungi [6–7]. Its derivatives and ana-
logs were extensively synthesized and studied having broadmoiety,
2 P.-Y. Wang et al.range of biological activities, including antitumor, anti-
inflammatory, insecticidal, herbicidal, antifungal, and antibac-
terial activities [8–16]. Especially, their antibacterial activity
had evoked the interest of chemists. For example, the discov-
ered natural 3-acyltetramic acid kibdelomycin (bacterial type
II topoisomerase inhibitor) [17] was found exhibiting excellent
antibacterial activity toward both gram-positive pathogens
(methicillin-resistant Staphylococcus aureus, Streptococcus
pneumonia, and Enterococcus faecalis) and gram-negative
pathogen (Haemophilus influenza) with a minimum inhibitory
concentration (MIC) value ranging from 0.5 to 2.0 lg/mL.
Moloney and Jeong [18] had evaluated the antibacterial activ-
ity of a series of monocyclic 3-carboxamide tetramic acids, and
found that the designed compounds showed good bioactivity
against 4 species of gram-positive bacteria and 3 species of
gram-negative bacteria. Obviously, 4-hydroxy-1H-pyrrol-2
(5H)-one could serve as a functional building block for the
construction of promising molecules with diverse bioactivities.
Furthermore, a combination of substituents could be placed at
different positions of tetramic acid, which consequently pro-
vided many kinds of derivatives [19–20]. Therefore, the design
of compounds possessing 4-hydroxy-1H-pyrrol-2(5H)-one
group is a preferred strategy to explore novel high-efficient
bioactive molecules.
It is known that compounds bearing 1,3,4-oxadiazole scaf-
fold exhibited extensively biological activities, particularly in
antibacterial and antiviral fields [21–23]. Herein, a variety of
1-aryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing
1,3,4-oxadiazole moiety were designed and synthesized via
placing the natural substructure 1-aryl-4-hydroxy-1H-pyrrol-
2(5H)-one at the 2-postion of 1,3,4-oxadiazole through a sul-
fide bridging group (Fig. 1). All the target compounds were
bioassayed against plant pathogenic bacteria Xanthomonas
oryzae pv. oryzae (Xoo), Ralstonia solanacearum (R. solana-
cearum), and Xanthomonas axonopodis pv. citri (Xac). In the
past decades, the three bacteria resulted in a variety of fearful
plant diseases, such as rice bacterial leaf blight, tobacco bacte-
rial wilt, and citrus bacterial canker [24–26]. Meanwhile, their
antiviral activities toward Tobacco mosaic virus (TMV) were
also investigated.
2. Methods and materials
2.1. Chemistry
All the chemicals were purchased from Aladdin, and used as
received. And the organic solvents were distilled before used.
Melting points of the compounds were determined on a XT-
4 binocular microscope (Beijing Tech Instrument Co., China).
NMR spectra were obtained by using a JEOL-ECX-500
apparatus. Chemical shifts were reported in parts per million
(ppm) down field from TMS with the solvent resonance as
the internal standard. Coupling constants (J) were reported
in Hz and referred to apparent peak multiplications.
2.2. Synthesis protocols for intermediates 2 and 3
Intermediates 2 (substituted benzoyl hydrazine) and 3 (5-substi
tuted-1,3,4-oxadiazole-2-thiol) were prepared using our previ-
ously reported methods [22,24,27].Please cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
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Ethyl chloroacetate (22.40 mmol) was added into a mixture of
substituted aniline (18.66 mmol) and sodium acetate anhy-
drous (22.40 mmol) in 30 mL anhydrous ethanol, and then
the mixture was refluxed for 6–8 h. After that, the solvent
was removed under reduced pressure, and re-dissolved by
60 mL dichloromethane. The organic layer was washed by
water, brine, dried with sodium sulfate, filtered, and followed
by the removal of the solvent under vacuum. Finally, interme-
diates 5 was obtained by column chromatography on silica gel
and eluted with petrol ether-ethyl acetate (10:1) with the yield
about 80.0% [28].
2.4. Synthesis protocols for intermediates 6
Bromoacetyl bromide (23.29 mmol) was added dropwise into
a solution of 5 (15.52 mmol) in 30 mL anhydrous dichloro-
methane on ice bath. Then, the ice bath was removed, and
the mixture was stirred for 2 h at room temperature. After
that, the organic layer was washed by water, brine, dried
with sodium sulfate, filtered, and followed by the removal
of the solvent under vacuum. Finally, intermediates 6 was
obtained by column chromatography on silica gel and eluted
with petrol ether-ethyl acetate (10:1) with the yield about
67.0%.
2.5. Synthesis protocols for intermediates 7
Bromo-tailored intermediates 6 (1.12 mmol) was added into a
mixture of 3 (1.12 mmol) and K2CO3 (1.35 mmol) in 20 mL
acetone, and then the mixture was stirred for 6 h at room tem-
perature. After that, a lot of precipitates formed after adding
10 mL cooled water into the system, which were filtered,
washed by water, and dried under infrared lamp with the yield
about 61.0%.
2.6. General synthesis protocols for 8a–8s
Potassium tert-butylate (0.97 mmol) was added into a solution
of intermediate 7 (0.49 mmol) in 20 mL acetone. Then the mix-
ture was stirred at room temperature for 24 h. After that, a lot
of precipitates were observed and filtered to afford the crude
product, which was further purified by recrystallizing it from
methanol to afford the desired product (8a–8s).
2.6.1. 4-Hydroxy-1-phenyl-3-((5-phenyl-1,3,4-oxadiazol-2-yl)
thio)-1H-pyrrol-2(5H)-one (8a)
A yellow solid, yield 42.3%, m. p. 201–203 C; IR (KBr)
vmax(cm
1): 2360, 1774, 1741, 1638, 1635, 1501, 1385, 1187,
1063, 1019, 960, 932, 753, 687; 1H NMR (500 MHz, DMSO-
d6) d 7.92 (1H, d, J= 7.8 Hz, phenyl-H), 7.68 (3H, t,
J= 7.6 Hz, phenyl-H), 7.62 (2H, t, J= 6.6 Hz, phenyl-H),
7.54 (1H, t, J= 7.5 Hz, phenyl-H), 7.36 (2H, t, J= 6.9 Hz,
phenyl-H), 7.07 (1H, t, J= 7.8 Hz, phenyl-H), 4.63 (2H, s,
CH2);
13C NMR (125 MHz, DMSO-d6) d 178.2, 168.2, 163.8,
163.5, 139.9, 133.9, 132.2, 131.7, 129.4, 128.5, 123.5, 122.7,
118.7, 51.3; MS (ESI) m/z: 352.1 [M+H]+.ryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
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Figure 1 Design strategy of the target compound.
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tolyl)-1H-pyrrol-2(5H)-one (8b)
A light yellow solid, yield 38.1%, m. p. 198–200 C; IR (KBr)
vmax(cm
1): 1637, 1617, 1591, 1566, 1517, 1476, 1427, 1387,
1293, 1238, 798, 698; 1H NMR (500 MHz, DMSO-d6) d 7.89
(2H, d, J= 6.9 Hz, phenyl-H), 7.58 (2H, d, J= 7.2 Hz,
phenyl-H), 7.54 (3H, d, J= 8.5 Hz, phenyl-H), 7.13 (2H, d,
J= 8.5 Hz, phenyl-H), 4.59 (2H, s, CH2), 2.23 (3H, s, CH3);
13C NMR (125 MHz, DMSO-d6) d 177.8, 168.0, 165.7, 162.7,
137.5, 132.6, 132.5, 130.0, 129.8, 126.8, 123.5, 118.7, 51.3,
20.9; MS (ESI) m/z: 366.1 ([M+H]+).
2.6.3. 1-(4-Chlorophenyl)-4-hydroxy-3-((5-phenyl-1,3,4-
oxadiazol-2-yl)thio)-1H-pyrrol-2(5H)-one (8c)
A light yellow solid, yield 37.6%, m. p. 145–147 C; IR (KBr)
vmax(cm
1): 1777, 1694,1615, 1493, 1465, 1437, 1379, 1298,
1207, 1094, 1006, 827, 701; 1H NMR (500 MHz, DMSO-d6)
d 12.57 (1H, s, OH), 7.92 (2H, d, J= 7.0 Hz, phenyl-H),
7.80 (2H, d, J= 7.6 Hz, phenyl-H), 7.73 (1H, d, J= 9.0 Hz,
phenyl-H), 7.57 (2H, d, J= 8.6 Hz, phenyl-H), 7.41 (2H, d,
J= 8.9 Hz, phenyl-H), 4.64 (2H, s, CH2).
13C NMR
(125 MHz, DMSO-d6) d 178.4, 168.4, 165.7, 162.7, 155.0,
154.3, 132.6, 132.0, 130.0, 129.8, 129.2, 126.9, 125.8, 120.1,
51.3; MS (ESI) m/z: 386.1 ([M+H]+).
2.6.4. 4-Hydroxy-3-((5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)-1-phenyl-1H-pyrrol-2(5H)-one (8d)
A light yellow solid, yield 46.2%, m. p. 136–138 C; IR (KBr)
vmax(cm
1): 2958, 2836, 1775, 1585, 1560, 1493, 1480, 1437,
1390, 1294, 1176, 1048, 852, 799, 693, 688; 1H NMR
(500 MHz, DMSO-d6) d 7.66 (2H, d, J= 8.0 Hz, phenyl-H),
7.46 (2H, d, J= 5.0 Hz, phenyl-H), 7.34 (3H, dd, J= 18.8,
11.2 Hz, phenyl-H), 7.16 (1H, d, J= 4.0 Hz, phenyl-H), 7.04
(1H, t, J= 7.3 Hz, phenyl-H), 4.62 (2H, s, CH2), 3.78 (3H,
s, CH3O);
13C NMR (125 MHz, DMSO-d6) d 178.1, 168.2,
165.6, 162.8, 160.2, 140.0, 131.3, 129.4, 124.7, 123.5, 119.2,
118.7, 118.6, 111.7, 88.3, 56.0, 51.3; MS (ESI) m/z: 382.1 ([M
+H]+).
2.6.5. 4-Hydroxy-3-((5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)-1-(p-tolyl)-1H-pyrrol-2(5H)-one (8e)
A white solid, yield 43.7%, m. p. 182–183 C; IR (KBr)
vmax(cm
1): 2941, 2840, 1694, 1615, 1589, 1560, 1510, 1492,
1465, 1435, 1380, 1292, 1261, 1230, 1204, 1166, 1158, 1052,
873, 827, 781, 748; 1H NMR (500 MHz, DMSO-d6) d 7.54
(2H, d, J= 8.0 Hz, phenyl-H), 7.46 (2H, d, J= 4.8 Hz,
phenyl-H), 7.37 (1H, s, phenyl-H), 7.16 (1H, d, J= 4.5 Hz,
phenyl-H), 7.13 (2H, d, J= 8.2 Hz, phenyl-H), 4.58 (2H, s,
CH2), 3.79 (3H, s, OCH3), 2.24 (3H, s, CH3);
13C NMR
(125 MHz, DMSO-d6) d 177.7, 168.0, 165.6, 162.8, 160.2,Please cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
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56.0, 51.3, 20.8; MS (ESI) m/z: 396.1 ([M+H]+).
2.6.6. 1-(4-Fluorophenyl)-4-hydroxy-3-((5-(3-
methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)-1H-pyrrol-2(5H)-
one (8f)
A white solid, yield 30.1%, m. p. 204–206 C; IR (KBr)
vmax(cm
1): 2928, 2850, 1753, 1714, 1648, 1624, 1603, 1487,
1419, 1391, 1355, 1310, 1224, 1092, 1027, 1015, 904, 840,
750, 729; 1H NMR (500 MHz, DMSO-d6) d 7.67 (2H, d,
J= 9.1 Hz, phenyl-H), 7.46 (2H, d, J= 5.4 Hz, phenyl-H),
7.37 (1H, s, phenyl-H), 7.22–7.13 (3H, m, phenyl-H), 4.61
(2H, s, CH2), 3.79 (3H, s, OCH3);
13C NMR (125 MHz,
DMSO-d6) d 178.0, 165.6, 162.8, 160.2, 136.4, 131.4, 124.7,
120.7, 119.2, 118.6, 116.0, 115.9, 111.7, 56.0, 51.5; MS (ESI)
m/z: 400.2 ([M+H]+).
2.6.7. 3-((5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-phenyl-1H-pyrrol-2(5H)-one (8g)
A white solid, yield 37.8%, m. p. 190–192 C; IR (KBr)
vmax(cm
1): 2625, 1690, 1659, 1596, 1553, 1510, 1483, 1431,
1378, 1230, 1214, 1160, 1094, 1036, 831, 799, 775, 752; 1H
NMR (500 MHz, DMSO-d6) d 7.89 (1H, d, J= 7.8 Hz,
phenyl-H), 7.66 (3H, d, J= 8.0 Hz, phenyl-H), 7.60 (1H, t,
J= 7.7 Hz, phenyl-H), 7.51 (1H, t, J= 7.7 Hz, phenyl-H),
7.33 (2H, t, J= 6.9 Hz, phenyl-H), 7.04 (1H, t, J= 7.3 Hz,
phenyl-H), 4.60 (2H, s, CH2);
13C NMR (125 MHz, DMSO-
d6) d 178.3, 168.2, 163.8, 139.9, 133.9, 132.2, 131.7, 129.4,
128.5, 123.5, 122.8, 118.7, 51.7; MS (ESI) m/z: 386.1 ([M
+H]+).
2.6.8. 3-((5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-(4-methoxyphenyl)-1H-pyrrol-2(5H)-one (8h)
A yellow solid, yield 32.8%, m. p. 187–189 C; IR (KBr)
vmax(cm
1):1817, 1773, 1654, 1617, 1516, 1427, 1382, 1185,
1169, 1062, 1019, 952, 836, 809, 768; 1H NMR (500 MHz,
DMSO-d6) d 7.68 (2H, d, J= 4.4 Hz, phenyl-H), 7.46 (2H,
d, J= 3.8 Hz, phenyl-H), 7.37 (1H, s, phenyl-H), 7.21–7.14
(3H, m, phenyl-H), 4.63 (2H, s, CH2), 3.79 (3H, s, OCH3);
13C NMR (125 MHz, DMSO-d6) d 177.8, 168.0, 165.6, 162.8,
160.2, 137.5, 132.5, 131.4, 129.8, 124.7, 119.1, 118.8, 118.6,
111.6, 55.9, 51.3; MS (ESI) m/z: 416.1 ([M+H]+).
2.6.9. 3-((5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-1-(4-
fluorophenyl)-4-hydroxy-1H-pyrrol-2(5H)-one (8i)
A white solid, yield 36.9%, m. p. 190–191 C; IR (KBr)
vmax(cm
1): 2939, 2641, 1635, 1588, 1564, 1504, 1484, 1435,
1390, 1293, 1227, 1192, 1088, 1034, 821, 760, 729, 689; 1H
NMR (500 MHz, DMSO-d6) d 7.88 (2H, d, J= 5.2 Hz,
phenyl-H), 7.67 (3H, d, J= 5.2 Hz, phenyl-H), 7.58 (1H, t,ryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
2
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(2H, s, CH2);
13C NMR (125 MHz, DMSO-d6) d 178.3, 168.2,
163.8, 163.5, 136.4, 133.9, 132.2, 131.7, 128.5, 122.7, 120.7,
120.6, 116.1, 115.9, 51.5; MS (ESI) m/z: 404.0 ([M+H]+).
2.6.10. 3-((5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-(4-methoxyphenyl)-1H-pyrrol-2(5H)-one (8j)
A light yellow solid, yield 51.2%, m. p. 199–200 C; IR (KBr)
vmax(cm
1): 2836, 2610, 1592, 1515, 1478, 1437, 1386, 1289,
1242, 1168, 1042, 836, 809, 738, 720; 1H NMR (500 MHz,
DMSO-d6) d 7.68 (2H, dd, J= 9.3, 4.9 Hz, phenyl-H), 7.46
(2H, d, J= 6.1 Hz, phenyl-H), 7.37 (1H, d, J= 3.8 Hz,
phenyl-H), 7.15–7.19 (3H, m, phenyl-H), 4.61 (2H, s, CH2),
3.79 (3H, s, OCH3);
13C NMR (125 MHz, DMSO-d6) d
178.1, 165.5, 162.7, 160.2, 136.4, 131.4, 124.7, 120.7, 120.6,
119.2, 118.6, 116.0, 115.9, 111.7, 56.0, 51.5; MS (ESI) m/z:
416.1 ([M+H]+).
2.6.11. 3-((5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-1-
(4-fluorophenyl)-4-hydroxy-1H-pyrrol-2(5H)-one (8k)
A white solid, yield 30.1%, m. p. 177–178 C; IR (KBr)
vmax(cm
1): 1697, 1617, 1558, 1510, 1460, 1379, 1229, 1160,
1066, 1027, 885, 826, 777, 748; 1H NMR (500 MHz, DMSO-
d6) d 7.85–7.89 (2H, m, phenyl-H), 7.67 (3H, d, J= 5.6 Hz,
phenyl-H), 7.59 (1H, t, J= 8.0 Hz, phenyl-H), 7.17 (2H, t,
J= 8.7 Hz, phenyl-H), 4.60 (2H, s, CH2);
13C NMR
(125 MHz, DMSO-d6) d 184.4, 178.4, 168.2, 157.2, 136.4,
134.6, 132.4, 132.1, 126.3, 125.6, 125.5, 120.7, 120.6, 116.0,
115.9, 74.4, 51.6; MS (ESI) m/z: 404.0 ([M+H]+).
2.6.12. 3-((5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-phenyl-1H-pyrrol-2(5H)-one (8l)
A yellow solid, yield 34.9%, m. p. 143–145 C; IR (KBr)
vmax(cm
1): 2925, 2347, 1875, 1833, 1640, 1580, 1473, 1387,
1171, 1092, 1066, 1012, 968, 834, 753, 726; 1H NMR
(500 MHz, DMSO-d6) d 7.85–7.89 (2H, m, phenyl-H), 7.67
(3H, d, J= 5.2 Hz, phenyl-H), 7.58 (1H, t, J= 7.9 Hz,
phenyl-H), 7.18 (2H, t, J= 8.9 Hz, phenyl-H), 4.62 (2H, s,
CH2);
13C NMR (125 MHz, DMSO-d6) d 178.3, 168.2, 164.6,
163.3, 136.4, 134.6, 132.4, 132.1, 126.3, 125.6, 125.4, 120.6,
120.6, 116.1, 115.9, 87.8, 51.5; MS (ESI) m/z: 386.1 ([M
+H]+).
2.6.13. 3-((5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-(p-tolyl)-1H-pyrrol-2(5H)-one (8m)
A light yellow solid, yield 50.2%, m. p. 175–176 C; IR (KBr)
vmax(cm
1): 2916, 1692, 1615, 1586, 1516, 1489, 1465, 1433,
1379, 1275, 1260, 1201, 1167, 1094, 1066, 1011, 839, 812,
750, 727; 1H NMR (500 MHz, DMSO-d6) d 7.99 (2H, d,
J= 14.1 Hz, phenyl-H), 7.57 (2H, d, J= 8.5 Hz, phenyl-H),
7.44 (2H, t, J= 8.8 Hz, phenyl-H), 7.17 (2H, d, J= 8.4 Hz,
phenyl-H), 4.62 (2H, s, CH2), 2.27 (3H, s, CH3);
13C NMR
(125 MHz, DMSO-d6) d 177.9, 168.1, 165.0, 1643.0, 147.0,
137.3, 130.2, 129.8, 128.7, 122.4, 118.8, 116.4, 87.2, 51.3,
20.9; MS (ESI) m/z: 400.2 ([M+H]+).
2.6.14. 3-((5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-1-
(4-fluorophenyl)-4-hydroxy-1H-pyrrol-2(5H)-one (8n)
A yellow solid, yield 36.6%, m. p. 229–231 C; IR (KBr)
vmax(cm
1): 1635, 1617, 1570, 1565, 1555, 1508, 1437, 1387,Please cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
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DMSO-d6) d 7.83 (2H, d, J= 8.6 Hz, phenyl-H), 7.66 (2H,
dd, J= 9.1, 4.9 Hz, phenyl-H), 7.59 (2H, d, J= 8.5 Hz,
phenyl-H), 7.04 (2H, t, J= 8.9 Hz, phenyl-H), 3.84 (2H, s,
CH2);
13C NMR (125 MHz, DMSO-d6) d 178.2, 168.3, 165.6,
162.8, 160.2, 140.0, 131.4, 129.4, 124.7, 123.5, 119.1, 118.6,
111.6, 51.3; MS (ESI) m/z: 404.0 ([M+H]+).2.6.15. 1-(4-Chlorophenyl)-3-((5-(4-chlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)-4-hydroxy-1H-pyrrol-2(5H)-one (8o)
A yellow solid, yield 41.3%, m. p. 168–169 C; IR (KBr)
vmax(cm
1): 1830, 1825, 1776, 1749, 1692, 1617, 1493, 1465,
1431, 1409, 1379, 1298, 1280, 1203, 1092, 1012, 968, 821,
748, 726; 1H NMR (500 MHz, DMSO-d6) d 11.03 (1H, s,
OH), 8.21 (2H, d, J= 8.6 Hz, phenyl-H), 7.92 (2H, d,
J= 8.0 Hz, phenyl-H), 7.80 (2H, d, J= 8.4 Hz, phenyl-H),
7.62 (2H, d, J= 8.0 Hz, phenyl-H), 4.39 (2H, s, CH2);
13C
NMR (125 MHz, DMSO-d6) d 186.4, 173.5, 163.9, 138.8,
136.7, 130.1, 128.3, 122.8, 118.5, 118.4, 115.5, 115.3, 54.7;
MS (ESI) m/z: 420.0 ([M+H]+).
2.6.16. 3-((5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-phenyl-1H-pyrrol-2(5H)-one (8p)
A gray white solid, yield 45.9%, m. p. 169–171 C; IR (KBr)
vmax(cm
1): 2607, 1781, 1637, 1615, 1601, 1585, 1575, 1499,
1478, 1437, 1389, 1223, 1174, 1157, 1069, 842, 758; 1H NMR
(500 MHz, DMSO-d6) d 7.95 (2H, d, J= 6.8 Hz, phenyl-H),
7.66 (2H, d, J= 7.9 Hz, phenyl-H), 7.39 (2H, t, J= 8.7 Hz,
phenyl-H), 7.33 (2H, t, J= 7.2 Hz, phenyl-H), 7.04 (1H, t,
J= 7.2 Hz, phenyl-H), 4.63 (2H, s, CH2);
13C NMR
(125 MHz, DMSO-d6) d 178.0, 168.2, 165.0, 162.7, 139.9,
129.6, 129.6, 129.4, 128.7, 123.5, 120.2, 118.6, 117.4, 117.2,
88.4, 51.2; MS (ESI) m/z: 370.1 ([M+H]+).
2.6.17. 3-((5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)-4-
hydroxy-1-(p-tolyl)-1H-pyrrol-2(5H)-one (8q)
A white solid, yield 43.2%, m. p. 212–213 C; IR (KBr)
vmax(cm
1): 1694, 1617, 1609, 1518, 1503, 1460, 1431, 1379,
1299, 1278, 1264,1246, 1235, 1208, 1160, 1072, 841, 811, 749,
732; 1H NMR (500 MHz, DMSO-d6) d 7.94 (2H, d,
J= 5.3 Hz, phenyl-H), 7.53 (2H, d, J= 8.5 Hz, phenyl-H),
7.39 (2H, t, J= 8.8 Hz, phenyl-H), 7.13 (2H, d, J= 8.4 Hz,
phenyl-H), 4.58 (2H, s, CH2), 2.23 (3H, s, CH3);
13C NMR
(125 MHz, DMSO-d6) d 177.7, 168.0, 165.6, 165.0, 163.7,
162.7, 137.5, 132.5, 129.8, 129.6, 129.6, 120.3, 118.8, 117.4,
117.2, 88.5, 51.3, 20.9; MS (ESI) m/z: 384.2 ([M+H]+).
2.6.18. 1-(4-Fluorophenyl)-3-((5-(4-fluorophenyl)-1,3,4-
oxadiazol-2-yl)thio)-4-hydroxy-1H-pyrrol-2(5H)-one (8r)
A white solid, yield 35.6%, m. p. 176–177 C; IR (KBr)
vmax(cm
1): 1696, 1617, 1610, 1513, 1504, 1461, 1431, 1380,
1249, 1241, 1209, 1161, 1072, 1027, 830, 748, 732, 623; 1H
NMR (500 MHz, DMSO-d6) d 7.95 (2H, d, J= 7.2 Hz,
phenyl-H), 7.67 (2H, d, J= 9.0 Hz, phenyl-H), 7.40 (2H, d,
J= 6.2 Hz, phenyl-H), 7.17 (2H, d, J= 4.7 Hz, phenyl-H),
4.61 (2H, s, CH2);
13C NMR (125 MHz, DMSO-d6) d 178.3,
168.3, 165.6, 165.0, 163.6, 162.8, 136.4, 130.9, 129.6, 129.6,
120.6, 120.5, 120.2, 117.4, 117.2, 116.1, 115.9, 51.5; MS (ESI)
m/z: 388.1 ([M+H]+).ryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
2
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oxadiazol-2-yl)thio)-4-hydroxy-1H-pyrrol-2(5H)-one (8s)
A light yellow solid, yield 30.8%, m. p. 195–196 C; IR (KBr)
vmax(cm
1): 1776, 1703, 1619, 1616, 1608, 1494, 1465, 1441,
1416, 1380, 1342, 1228, 1155, 1096, 1088, 840, 823, 732, 622;
1H NMR (500 MHz, DMSO-d6) d 12.58 (1H, s, OH), 7.99
(2H, d, J= 5.6 Hz, phenyl-H), 7.84 (2H, d, J= 6.4 Hz,
phenyl-H), 7.73 (2H, d, J= 6.8 Hz, phenyl-H), 7.41 (2H, d,
J= 6.6 Hz, phenyl-H), 4.63 (2H, s, CH2);
13C NMR
(125 MHz, DMSO-d6) d 168.5, 162.8, 153.6, 138.9, 129.6,
129.6, 129.2, 128.5, 128.4, 120.3, 120.1, 117.4, 117.2, 117.1,
116.9, 51.3; MS (ESI) m/z: 404.0 ([M+H]+).
2.7. In vitro antibacterial bioassay
In our study, all the synthesized target compounds were eval-
uated for their antibacterial activities against Xoo, R. solana-
cearum, and Xac by the turbidimeter test in vitro.
Dimethylsulfoxide in sterile distilled water served as a blank
control, Bismerthiazol and Thiodiazole Copper served as pos-
itive controls. Approximately 40 lL of solvent NB (1.5 g beef
extract, 2.5 g peptone, 0.5 g yeast powder, 5.0 g glucose, and
500 mL distilled water; pH = 7.0–7.2) containing Xoo (R. sola-
nacearum or Xac), incubated on the phase of logarithmic
growth, was added to 5 mL of solvent NB containing the test
compounds and positive control. The inoculated test tubes
were incubated at 28 ± 1 C and continuously shaken at
180 rpm for 24–48 h until the bacteria were incubated on the
logarithmic growth phase. The growth of the cultures was
monitored on a microplate reader by measuring the optical
density at 595 nm (OD595) given by turbidity corrected val-
ues = ODbacterial wilt  ODno bacterial wilt, and the inhibition
rate I was calculated by I= (C  T)/C  100%. C is the cor-
rected turbidity values of bacterial growth on untreated NB
(blank control), and T is the corrected turbidity values of bac-
terial growth on treated NB. The results of antibacterial activ-
ities (expressed by EC50) against Xoo, R. solanacearum, and
Xac were calculated with SPSS 17.0 software. The experiment
was repeated three times.
2.8. In vivo antiviral bioassay
2.8.1. Curative activity of the target compounds against TMV
in vivo
Growing Nicotiana tabacum L. leaves of the same age were
selected. The leaves were inoculated with TMV (concentration
of 6  103 mg/mL) by dipping and brushing the whole leaves,
which had previously been scattered with silicon carbide. The
leaves were then washed with water after inoculation for
0.5 h. The compound solution was smeared on the left side
of the leaves, and the solvent was smeared on the right side
as the control. The number of local lesions was counted and
recorded 3–4 d after inoculation. Three replicates were set up
for each.
2.8.2. Protection activity of the target compounds against TMV
in vivo
The compound solutions were smeared on the left side of the
N. tabacum L. leaves, and the solvents were smeared on the
right side as the control sample for growing N. tabacum L.
leaves. After 12 h, crude TMV (concentration ofPlease cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2016.10.006  103 mg/mL) was inoculated on whole leaves at the same
concentration on each side of the leaves, which were previously
scattered with silicon carbide. After 0.5 h, the leaves were
washed with water and then dried. The number of local lesions
was recorded 3–4 d after inoculation. Three replicates were
used for each compound. The inhibitory rate of the compound
was calculated according to the following formula:
Inhibition rate ¼ ½ðaverage local lesion number of control
ðnot treated with compoundÞ
 average local lesion number
smeared with drugsÞ
=average local lesion number of control
ðnot treated with compoundÞ  100%:3. Results and discussion
3.1. Chemistry
The structures and synthetic route for the target compounds
(8a–8s) are shown in Fig. 2. The important intermediate (5-sub
stituted-1,3,4-oxadiazole-2-thiol (3)) was obtained by treating
the starting material (substituted benzoic carboxylic acid (1))
with four steps including esterification, hydrazidation, cycliza-
tion and acidification [22,24,27]. Another intermediate (6) was
synthesized via a two-step substitution reaction form
substituted-aniline (4) [28]. By combining intermediates (3)
and (6) together in a solution of K2CO3 in acetone, a crucial
intermediate (7) was provided. Finally, the title compounds
(8a–8s) were synthesized by adding potassium tert-butylate
into a solution of intermediate 7 in acetone [29–30]. All the title
compounds were characterized by IR, 1H NMR, 13C NMR,
and MS.
3.2. Antibacterial activity
The antibacterial activities toward gram-negative pathogenic
bacteria Xoo, R. solanacearum and Xac were performed by tur-
bidimeter test in vitro [27,31], and the commercial agricultural
antibacterial bismerthiazol (BT) and thiodiazole copper (TC)
were exploited as positive controls under the same conditions.
As shown in Table 1, all the target compounds showed inhibi-
tion effects against the three bacteria at the concentrates of 200
or 100 lg/mL. Among these derivatives, 8a, 8b, 8c, 8d, 8j, 8l,
and 8p exhibited excellent bactericidal effect against Xoo, with
the inhibition rates ranging from 91.4% to 97.9% at the con-
centrate of 200 lg/mL, which were better than that of BT
(56.1%); when the dosage of tested compounds decreased to
100 lg/mL, compound 8a, 8c, 8d, and 8l still maintained the
strongest antibacterial functions against Xoo, suggesting that
the combination of the bioactive scaffolds of 1-aryl-4-
hydroxy-1H-pyrrol-2(5H)-one and 1,3,4-oxadiazole moiety
did endow these compounds with favorable bioactivities. Fur-
ther studies revealed that compound 8a, 8b, 8c, 8d, and 8l
exerted admirable inhibition effects against Xoo with the
half-maximal effective concentration (EC50) values of 8.6,
40.2, 17.6, 39.6, and 7.3 lg/mL (Table 2), respectively, which
were better than that of BT (EC50 = 92.6 lg/mL). Bioassay
results demonstrated that the designed compounds displayed
certain bactericidal effect toward R. solanacearum. Studiesryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
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Figure 2 Synthetic route of the title compounds (8a–8s).
Table 1 Inhibition effect of the title compounds against Xoo, R. solanacearum, and Xac.
Compd. Inhibition (%)
Xoo R. solanacearum Xac
200 lg/mL 100 lg/mL 200 lg/mL 100 lg/mL 200 lg/mL 100 lg/mL
8a 95.7 ± 0.6 95.7 ± 0.1 59.4 ± 3.1 27.1 ± 3.9 74.8 ± 9.2 53.8 ± 6.1
8b 94.1 ± 4.5 56.3 ± 6.2 33.2 ± 0.1 27.1 ± 3.3 54.5 ± 0.1 29.8 ± 4.6
8c 95.2 ± 0.5 93.0 ± 4.9 40.5 ± 5.4 22.6 ± 4.3 27.1 ± 5.0 15.8 ± 1.9
8d 97.6 ± 1.0 96.2 ± 0.4 33.8 ± 4.9 28.6 ± 3.2 87.3 ± 3.2 65.0 ± 6.7
8e 53.4 ± 9.1 51.5 ± 3.3 26.3 ± 2.8 19.4 ± 7.5 36.0 ± 2.8 24.7 ± 3.1
8f 58.9 ± 4.5 23.6 ± 4.8 22.7 ± 1.2 17.6 ± 1.2 33.1 ± 5.8 28.7 ± 2.0
8g 36.9 ± 6.2 30.7 ± 3.8 20.5 ± 1.8 28.7 ± 7.1 26.5 ± 7.8 19.9 ± 7.7
8h 32.3 ± 6.2 19.6 ± 6.0 31.1 ± 7.9 15.7 ± 0.7 34.1 ± 4.3 23.6 ± 7.5
8i 24.9 ± 0.5 17.2 ± 2.0 28.2 ± 1.3 17.5 ± 3.0 36.3 ± 6.2 23.4 ± 4.7
8j 91.4 ± 2.1 36.1 ± 1.0 21.1 ± 9.9 15.7 ± 0.7 39.5 ± 5.1 23.1 ± 5.6
8k 33.6 ± 4.8 26.0 ± 6.7 25.2 ± 3.2 23.0 ± 4.7 22.9 ± 6.6 18.1 ± 2.4
8l 97.9 ± 1.0 97.9 ± 0.4 31.1 ± 2.5 25.5 ± 1.7 82.0 ± 4.5 59.3 ± 9.5
8m 16.1 ± 8.3 9.6 ± 8.7 17.7 ± 5.0 11.3 ± 2.1 46.6 ± 1.5 33.7 ± 5.9
8n 39.0 ± 6.0 29.4 ± 8.8 31.1 ± 2.9 24.0 ± 4.8 23.7 ± 4.5 22.7 ± 5.4
8o 66.0 ± 5.3 19.3 ± 6.3 27.6 ± 7.2 16.5 ± 5.2 74.3 ± 4.4 35.3 ± 8.5
8p 97.0 ± 0.1 26.8 ± 3.9 34.6 ± 2.2 28.1 ± 1.5 31.9 ± 4.8 24.2 ± 9.3
8q 22.6 ± 3.1 11.8 ± 5.1 14.7 ± 6.3 8.6 ± 6.1 21.8 ± 3.5 15.0 ± 1.7
8r 14.6 ± 6.4 8.7 ± 4.1 39.3 ± 3.3 30.2 ± 1.2 39.0 ± 9.6 36.4 ± 1.5
8s 59.2 ± 5.6 23.5 ± 5.9 22.3 ± 5.4 16.0 ± 4.0 27.0 ± 4.8 23.6 ± 5.1
BT 56.1 ± 7.3 49.3 ± 5.4 / / / /
TC / / 92.5 ± 2.7 52.3 ± 4.9 51.4 ± 2.4 22.7 ± 2.6
6 P.-Y. Wang et al.on the inhibition effect of title compounds suggested that 8a,
8d, 8l, and 8o exerted the strongest inhibition effect against
Xac with the inhibition rates of 74.8, 87.3, 82.0, and 74.3%
at the dosage of 200 lg/mL, respectively, which were better
than that of TC (51.4%). It was noted that most of the title
compounds exposed better antibacterial activity toward Xac
than that of TC (22.7%) at the concentrate of 100 lg/mL.
Given the above results, compounds 8a and 8l could be further
studied and explored as alternative antibacterial agents.Please cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2016.10.003.3. Preliminary structure-antibacterial activity relationship
(SAAR) analysis toward Xoo and Xac
Preliminary SAAR analysis toward Xoo was elucidated
according to the bioassay results. It was noteworthy that the
substituents both on the phenyl ring (R1) and N-phenyl group
(R2) showed a significant impact on the antibacterial activity.
For example, it was disadvantageous to anti-bacterial activityryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
2
Table 2 EC50 values of 8a, 8b, 8c, 8d, and 8l against pathogen Xoo.
Compd. R1 R2 Regression equation r
2 EC50 (lg/mL)
8a H H y= 1.453x+ 3.642 0.93 8.6 ± 3.7
8b H 4-CH3 y= 0.764x+ 3.774 0.97 40.2 ± 4.3
8c H 4-Cl y= 0.833x+ 3.963 0.99 17.6 ± 2.9
8d 3-CH3O H y= 1.703x+ 2.280 0.99 39.6 ± 2.7
8l 4-Cl H y= 1.836x+ 3.415 0.93 7.3 ± 2.5
BT / / y= 1.499x+ 2.052 0.98 92.6 ± 2.1
Table 3 Antiviral activities of the target compounds against TMV in vivo at 500 lg/mL.
Compd. Curative activity (%) Protective activity (%) Compd. Curative activity (%) Protective activity (%)
8a 42.3 ± 2.1 40.2 ± 2.7 8k 34.6 ± 4.4 40.2 ± 5.1
8b 41.5 ± 4.4 30.3 ± 2.0 8l 41.9 ± 1.1 50.9 ± 3.9
8c 41.8 ± 6.9 51.7 ± 4.2 8m 39.5 ± 3.4 50.2 ± 2.1
8d 37.1 ± 4.3 25.7 ± 2.1 8n 26.3 ± 1.2 36.1 ± 2.3
8e 41.1 ± 3.3 25.0 ± 3.4 8o 40.3 ± 2.2 45.2 ± 3.8
8f 41.8 ± 6.6 35.3 ± 2.0 8p 39.1 ± 3.7 59.5 ± 3.1
8g 37.8 ± 5.4 33.2 ± 2.3 8q 36.1 ± 3.7 31.1 ± 2.3
8h 33.5 ± 3.9 50.2 ± 1.1 8r 41.1 ± 2.6 48.9 ± 4.1
8i 26.4 ± 3.6 36.2 ± 3.4 8s 40.8 ± 4.7 54.7 ± 4.7
8j 37.4 ± 7.6 33.2 ± 2.6 NNM 55.7 ± 2.6 66.8 ± 2.7
Synthesis and bioactivities of 1-aryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives 7when the sterically hindered group ((R2 = 4-CH3, 8b,
EC50 = 40.2 lg/mL), or (R2 = 4-Cl, 8c, EC50 = 17.6 lg/
mL)) was introduced on the N-benzene ring in comparison
of that of R2 = H (8a, EC50 = 8.6 lg/mL), suggesting that a
large substituent (R2) was not favorable for the bioactivity of
the target compounds. This phenomenon was further con-
firmed through the comparison of the bioactivity of com-
pounds (8d–8f, 8g–8i, 8l–8o, and 8p–8s). Additionally, the
position of the substituent also affected the bactericidal activ-
ity, the order of activities followed para (R1 = 4-Cl, 8n)
> meta (R1 = 3-Cl, 8k) > ortho (R1 = 2-Cl, 8i), para
(R1 = 4-Cl, 8l) > ortho (R1 = 2-Cl, 8g). Given the above
results, the steric hindrance of a substituent on the benzene
ring could be considered as one of the major factors for the
future design of this kind of structures.
Preliminary SAAR analysis toward Xac showed that the
bioactivity was decreased with introducing steric hindrance
of a substituent on the N-benzene ring, such as the order of
activities followed R2 = H (8a, 74.8%, 200 lg/mL)
> R2 = 4-CH3 (8b, 54.5%, 200 lg/mL) or R2 = 4-Cl (8c,
27.1%, 200 lg/mL). This result could be further verified by
comparing the bioactivity of 8d–8f, 8j–8k, and 8l–8o, respec-
tively. It is worth mentioning that compound bearing an
electron-donating group (3-CH3O, 8d, 87.3%) exhibited better
anti-bacterial activity than that of electron-withdrawing group
(2-Cl, 8g, 26.6%; 4-Cl, 8l, 82.0%; 4-F, 8p, 31.9%; 200 lg/mL).
3.4. Antiviral activity
The antiviral activity of the compounds (8a–8s) toward TMV
was evaluated in vivo as previously described [32–33], and the
commercial agent ningnanmycin (NNM) was chosen as the
positive control. As shown in Table 3, most of the target com-Please cite this article in press as: P.-Y. Wang et al., Synthesis and bioactivities of 1-a
Journal of Saudi Chemical Society (2016), http://dx.doi.org/10.1016/j.jscs.2016.10.00pounds demonstrated certain curative and protective activities
against TMV. Among them, compounds 8a, 8b, 8c, 8e, 8f, 8l,
8o, 8r, and 8s showed curative activity against TMV with the
curative rates ranging from 40.3% to 42.3%, which were lower
than that of NNM (55.7%); while compounds 8c, 8h, 8l, 8m,
8p, and 8s exhibited good protective activities against TMV
with values within 50.2–59.5% (NNM, 66.8%). Based on
above result, this kind of compounds possessed certain antivi-
ral activity toward TMV.
3.5. Preliminary structure-antiviral activity relationship analysis
toward TMV
In comparison of the curative activity against TMV, com-
pound without substituents on the benzene ring
(R1 = R2 = H, 8a, 42.3%, 500 lg/mL) exerted the strongest
therapeutic effect in vivo, suggesting that sterically hindered
group on the benzene ring was not favorable to the bioactivity.
The fact is that the protective activity against TMV of 8p
(R1 = 4-F, R2 = H, 59.5%, 500 lg/mL) exhibited the best
protective effect than that of other compounds.
4. Conclusions
In this paper, a series of 1-aryl-4-hydroxy-1H-pyrrol-2(5H)-
one derivatives possessing 1,3,4-oxadiazole moiety were
designed and synthesized by placing the natural substructure
1-aryl-4-hydroxy-1H-pyrrol-2(5H)-one at the 2-postion of
1,3,4-oxadiazole through a sulfide bridging group. Preliminary
bioassays suggested that these compounds not only exhibited
favorable antibacterial activity toward plant pathogenic bacte-
ria including Xoo, R. solanacearum, and Xac, but also showed
certain curative and protective activities against TMV. Furtherryl-4-hydroxy-1H-pyrrol-2(5H)-one derivatives bearing 1,3,4-oxadiazole moiety,
2
8 P.-Y. Wang et al.studies revealed that compound 8a and 8l exerted the best
antibacterial activity toward Xoo with EC50 values of 8.6 and
7.3 lg/mL, respectively, which were better than that of the
commercial agricultural antibacterial agent BT (EC50 = 92.6
lg/mL). Given the above results, this kind of compounds
could be further studied and explored as alternative antibacte-
rial agents.
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